The preliminary list of the 2023 medical insurance catalogue was announced, and a number of high-priced popular drugs were listed.

　　On the evening of August 18th, the website of the National Medical Insurance Bureau published the list of drugs that passed the preliminary examination of the 2023 National Medical Insurance Catalogue, and interpreted the formula.

　　According to the published information, from 9: 00 on July 1, 2023 to 17: 00 on July 14, 2023, the Medical Insurance Bureau received a total of 629 enterprise declaration information, involving 570 drugs (generic names, the same below). After examination, 390 drugs passed the preliminary examination.

　　Compared with 2022, the number of declared drugs has increased to some extent.One million needles of CAR-T therapy drugs, Aquilencel injection and Regioscel injection, as well as detrozumab for breast cancer drug injection, which was just approved in February this year.(trade name: Youhede) all appear on the list.

　　China’s first approved CAR-T product is Yikaida (Akilensai Injection) from Fosun Kate Company, which went on the market in June 2021, and the retail price was once as high as 1.2 million/bag (68ml). Previously, the drug also appeared in the preliminary list of medical insurance catalogue in 2021, but it did not enter the medical insurance catalogue in the end.

　　As a new generation of ADC drugs targeting HER2, detrtuzumab for injection (Youhede) was approved by National Medical Products Administration, China on February 21, 2023. It is used as a single drug to treat unresectable or metastatic HER2-positive adult breast cancer patients who have received one or more anti-HER2 drugs in the past. The domestic listing price is 8860 yuan/piece.

　　In the interpretation, the Medical Insurance Bureau said that some expensive drugs that were obviously beyond the basic medical insurance coverage passed the preliminary formal examination, which only indicated that the drugs met the declaration conditions and obtained the qualification to enter the next link. Whether this kind of drugs can finally enter the national medical insurance drug list still needs strict evaluation procedures, and then exclusive drugs need to be negotiated and non-exclusive drugs need to be auctioned, and only after successful negotiation or bidding can they be included in the list.

　　According to the relevant information of the document, the publicity time is August 18, 2023 — August 24th, for a week. Follow-up will further verify the relevant information according to the feedback received during the publicity period, and determine the scope of drugs that finally passed the formal review.